Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
Source: SeekingAlpha
2025-03-13 19:45:04 ET
More on Pharming, Pharming Group N.V., etc.
- Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
- Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO
- Pharming Group offers to buy Sweden's Abliva for SEK 0.45/shr
- Seeking Alpha’s Quant Rating on Pharming
- Historical earnings data for Pharming
Read the full article on Seeking Alpha
For further details see:
Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
Pharming Group N.V.
NASDAQ: PHAR
PHAR Trading
-1.77% G/L:
$16.07 Last:
6,811 Volume:
$16.10 Open:
PHAR Latest News
PHAR Stock Data
$1,106,258,522
65,794,170
N/A
5
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
